Spring Bank Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing novel therapeutics for oncology and inflammatory diseases, today announced a new clinical collaboration with Roche, to explore the co-administration of SB 11285, Spring Bank’s intravenously (IV)-administered STING (STimulator of INterferon Gene) agonist with Roche’s PD-L1 checkpoint inhibitor atezolizumab (Tecentriq) in patients with advanced solid tumors.
During the fourth quarter of 2019, Spring Bank dosed the first patient in the monotherapy dose escalation component of the intravenously-administered SB 11285 Phase 1a trial. This monotherapy dose escalation component will be followed by a combination dose escalation of IV SB 11285 with a checkpoint inhibitor (nivolumab) and with atezolizumab (Tecentriq) as an additional arm added to the combination dose escalation segment of the Phase 1a trial. By the end of 2020, Spring Bank plans to generate sufficient data from its Phase 1a/1b IV STING agonist program to enable advancement into a Phase 2 clinical trial.
“We are thrilled to announce a new clinical collaboration to explore our SB 11285 IV STING agonist in combination with atezolizumab (Tecentriq) in patients with advanced solid tumors,” said Atif Abbas, M.D., Vice President & Head of Oncology/Immunology Development at Spring Bank. Dr. Abbas continued, “We believe our IV-administered STING agonist has the ability to treat a broader range of cancers and patients when used in combination with checkpoint inhibitors by potentially enhancing their potency and effectiveness, and we look forward to being able to examine this effect with atezolizumab (Tecentriq) as well as other checkpoint inhibitors.”
As noted above, Phase 1a of the IV SB 11285 Phase 1 trial is a dose-escalation study with monotherapy followed by combination with one or more checkpoint inhibitors and is designed to determine a recommended Phase 2 dose. Phase 1b of the trial will explore IV SB 11285 antitumor activity in combination with a checkpoint inhibitor in selected tumor types. The trial is being conducted at multiple sites in the United States.
About Spring Bank Pharmaceuticals
Spring Bank Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery and development of a novel class of therapeutics using its proprietary small molecule nucleotide platform. The company designs its compounds to selectively target and modulate the activity of specific proteins implicated in various disease states. The company is developing its STING product portfolio with its lead clinical product candidate, SB 11285, an intravenously-administered immunotherapeutic agent for the treatment of selected cancers, its STING antagonist compounds for the treatment of a broad range of inflammatory diseases and its STING agonist ADC program for potential oncology applications. For more information, visit www.springbankpharm.com.